CLDX FY 2021 Earnings — Celldex Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CLDXCelldex Therapeutics, Inc.

$2B

FY 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$5M-37.3% YoY

Gross Profit

-$49M-1046.2% margin

Operating Income

-$71M-1531.8% margin

Net Income

-$71M-1516.0% margin

EPS (Diluted)

$-1.64

Cash Flow

Operating Cash Flow

-$61M

Free Cash Flow

-$62M

Stock-Based Comp.

$9M

Balance Sheet

Total Assets

$445M

Total Liabilities

$25M

Stockholders' Equity

$419M

Cash & Equivalents

$39M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$5M	$7M	-37.3%
Gross Profit	-$49M	-$35M	-38.6%
Operating Income	-$71M	-$63M	-12.5%
Net Income	-$71M	-$60M	-18.0%